KNSA Stock News & Catalysts

FEATURED

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion –– KPL-387 pivotal Phase

Summary

Oct 27, 2026, 7:30 AM ·Globe Newswire

RECENT

Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern

Oct 22, 2026, 4:01 PM ·Globe Newswire

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare

Sep 4, 2026, 4:01 PM ·Globe Newswire

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth

Aug 7, 2026, 4:01 PM ·Globe Newswire

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $980 - $995 million –– KPL-387 Phase 2 data

Jul 28, 2026, 7:30 AM ·Globe Newswire

Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026

LONDON, July 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 28, 2026 at 8:30 a.m. Eastern

Jul 23, 2026, 4:01 PM ·Globe Newswire

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in fireside chats at the following investor conferences in June: 2026

May 29, 2026, 4:01 PM ·Globe Newswire

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $930 - $945 million –– KPL-387 Phase 2

Apr 28, 2026, 7:30 AM ·Globe Newswire

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern

Apr 23, 2026, 4:01 PM ·Globe Newswire

Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis

– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media accompanying this announcement is available by clicking on this

Apr 8, 2026, 8:00 AM ·Globe Newswire

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference

LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:01 PM ·Globe Newswire

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2

Feb 24, 2026, 7:30 AM ·Globe Newswire

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 at 8:30 a.m. Eastern

Feb 19, 2026, 4:01 PM ·Globe Newswire

Kiniksa Pharmaceuticals Provides Corporate Update

– ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2

Jan 12, 2026, 7:30 AM ·Globe Newswire

Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference

LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026

Jan 7, 2026, 4:01 PM ·Globe Newswire

Kiniksa Pharmaceuticals International, plc KNSA · News